Abstract
A simple and green method is reported for the completely chemoselective synthesis of some new dicoumarol derivatives {3,3'-(2-aryl-2-oxoethylidene)bis[4-hydroxycoumarin]s} from the reaction of 4-hydroxycoumarin with arylglyoxals in a molar ratio of 2:1 respectively. The reactions efficiently promoted by titanium(IV) oxide nanoparticles as a heterogeneous catalyst via an on water process. Catalyst loading is very low and it shows recyclability.
Keywords: Titanium(IV) oxide nanoparticles, chemoselectivity, 3, 3'-(2-aryl-2-oxoethylidene)bis[4-hydroxycoumarin]s, catalysts, arylglyoxal.
Graphical Abstract
Letters in Organic Chemistry
Title:Synthesis of New and Known Dicoumarols in Aqueous Media: A Green and Convenient Procedure Promoted by Titanium(IV) Oxide Nanoparticles
Volume: 11 Issue: 8
Author(s): Saeed Khodabakhshi, Mozhgan Shahamirian and Mojtaba Baghernejad
Affiliation:
Keywords: Titanium(IV) oxide nanoparticles, chemoselectivity, 3, 3'-(2-aryl-2-oxoethylidene)bis[4-hydroxycoumarin]s, catalysts, arylglyoxal.
Abstract: A simple and green method is reported for the completely chemoselective synthesis of some new dicoumarol derivatives {3,3'-(2-aryl-2-oxoethylidene)bis[4-hydroxycoumarin]s} from the reaction of 4-hydroxycoumarin with arylglyoxals in a molar ratio of 2:1 respectively. The reactions efficiently promoted by titanium(IV) oxide nanoparticles as a heterogeneous catalyst via an on water process. Catalyst loading is very low and it shows recyclability.
Export Options
About this article
Cite this article as:
Khodabakhshi Saeed, Shahamirian Mozhgan and Baghernejad Mojtaba, Synthesis of New and Known Dicoumarols in Aqueous Media: A Green and Convenient Procedure Promoted by Titanium(IV) Oxide Nanoparticles, Letters in Organic Chemistry 2014; 11 (8) . https://dx.doi.org/10.2174/157017861108140613162852
DOI https://dx.doi.org/10.2174/157017861108140613162852 |
Print ISSN 1570-1786 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6255 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Application of Radiolabeled Antibodies in Targeting Therapy of Breast Cancer
Current Molecular Imaging (Discontinued) The Gene Expression Profiles of Medulloblastoma Cell Lines Resistant to Preactivated Cyclophosphamide
Current Cancer Drug Targets The Anti-Breast Cancer Potential of Bis-Isatin Scaffolds
Current Topics in Medicinal Chemistry Nanoparticles-Based Treatment for Bone Metastasis
Current Drug Targets Physiopathological Roles of P2X Receptors in the Central Nervous System
Current Medicinal Chemistry Membrane Localization of Estrogen Receptors
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Peripheral Immune Signatures in Alzheimer Disease
Current Alzheimer Research The Role of Tumor Suppressor Dysregulation in Prostate Cancer Progression
Current Drug Targets Pulmonary Infections in the Era of Biological Agents
Current Respiratory Medicine Reviews Bortezomib: A New Pro-Apoptotic Agent in Cancer Treatment
Current Cancer Drug Targets Engineered Nanoparticles for Improved Vasoactive Intestinal Peptide (VIP) Biomedical Applications
Recent Patents on Nanomedicine Evaluation of Anticancer Activities of Gallic Acid and Tartaric Acid Vectorized on Iron Oxide Nanoparticles
Drug Delivery Letters Drug Repositioning for Treatment of Movement Disorders: From Serendipity to Rational Discovery Strategies
Current Topics in Medicinal Chemistry Nanosized Tamoxifen-Porphyrin-Glucose [TPG] Conjugate: Novel Selective Anti-breast-cancer Agent, Synthesis and In Vitro Evaluations
Medicinal Chemistry Amplified Crosstalk Between Estrogen Binding and GFR Signaling Mediated Pathways of ER Activation Drives Responses in Tumors Treated with Endocrine Disruptors
Recent Patents on Anti-Cancer Drug Discovery Selective Chemokine Receptor-Targeted Depletion of Pathological Cells as A Therapeutic Strategy for Inflammatory, Allergic and Autoimmune Diseases
Recent Patents on Inflammation & Allergy Drug Discovery Nitroimidazole Radiopharmaceuticals in Hypoxia: Part II Cytotoxicity and Radiosensitization Applications
Current Radiopharmaceuticals Structure, Function, and Pathogenesis of SHP2 in Developmental Disorders and Tumorigenesis
Current Cancer Drug Targets Peptides Targeting Toll-Like Receptor Signalling Pathways for Novel Immune Therapeutics
Current Pharmaceutical Design Development of New Drugs that Act Through Membrane Receptors and Involve an Action of Inverse Agonism
Recent Patents on CNS Drug Discovery (Discontinued)